High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
By Hao Xu, L. Zhong, Jia-Qi Deng, Jiakuan Peng, H. Dan, Xin Zeng, Taiwen Li, Qianming Chen. International Journal of Oral Science, 2020
2,559 citations recorded by the source corpus.
It has been reported that ACE2 is the main host cell receptor of 2019-nCoV and plays a crucial role in the entry of virus into the cell to cause the final infection. To investigate the potential route of 2019-nCov infection on the mucosa of oral cavity, bulk RNA-seq profiles from two public databases including The Cancer Genome Atlas (TCGA) and Functional Annotation of The Mammalian Genome Cap Analysis of Gene Expression (FANTOM5 CAGE) dataset were collected. RNA-seq profiling data of 13 organ types with para-carcinoma normal tissues from TCGA and 14 organ types with normal tissues from FANTOM5 CAGE were analyzed in order to explore and validate the expression of ACE2 on the mucosa of oral cavity. Further, single-cell transcriptomes from an independent data generated in-house were used to identify and confirm the ACE2-expressing cell composition and proportion in oral cavity. The results demonstrated that the ACE2 expressed on the mucosa of oral cavity. Interestingly, this receptor was highly enriched in epithelial cells of tongue. Preliminarily, those findings have explained the basic mechanism that the oral cavity is a potentially high risk for 2019-nCoV infectious susceptibility and provided a piece of evidence for the future prevention strategy in dental clinical practice as well as daily life.
Subfields: Dermatology, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/63af0d8b639b0abe14d9be9eaa3a135bb9a9eaf1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection (2021, background): “ACE2 expression is detected in type II alveolar cells (AT2) [22–26], bronchial transient epithelial secretory cells respiratory epithelial cells [27], myocardial cells [22], endothelial cells and artery smooth muscle cells [22], oesophagus epithelial cells [22–24], neurons and glia [28], tongue epit”
- COVID-19, ACE2, and the cardiovascular consequences (2020, background): “23) as a coreceptor to gain intracellular entry into the lungs and brain (17, 30, 52, 53, 62).”
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response (2020, positive): “In supporting the process of entry of the virus into the host cell, SARS-CoV2 binds to the ACE2 receiver that is highly expressed in the lower respiratory tract such as type II alveolar cells (AT2) of the lungs, upper esophagus and stratified epithelial cells, and other cells such as absorptive ente”
- Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study (2020, background): “Lymphocytes express the coronavirus receptor ACE2 and may be a direct target of viruses.(5) (2) The virus might directly destroy lymphatic organs.”
- Coronavirus disease 2019 (COVID-19) pandemic and pregnancy (2020, neutral): “Although the expression of ACE2 is predominantly within type II alveolar cells of the lung, the receptor is also present in several extrapulmonary sites across the aerodigestive tract, including the mucosa of the oral cavity.(5) Patients with COVID19 thereforemanifest a spectrumof upper and lower re”
- Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach (2020, positive): “SARS-CoV-2 infection requires the binding of the virus to the membrane-bound form of ACE2 and internalization of the S protein of the virus to the extracellular domain of ACE2, a membrane receptor, with a high affinity of 15 nM to be internalized by the host cell [24,123].”
- Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis (2020, background): “Although the mechanism of significant lymphocyte reduction in severe COVID-19 remains unclear, there are hypothesis other than lymphocyte infiltration and sequestration in the lungs, gastrointestinal tracts, and or lymphoid tissues: (1) lymphocytes express the ACE2 receptor and may be a direct targe”
- The protein expression profile of ACE2 in human tissues (2020, result): “There are also other studies concluding that the ACE2 expression is considerably higher in other cells of the respiratory tract, such as ciliated or secretory cells 21, 22 , or in squamous epithelial cells of oral mucosa or esophagus 23, 24 .”